Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
eNq1mF1v2jAUhu/5FVEudkfSAO1gS6g21m5IrcZo0abdIJOcFDNjp/6gsF8/h9CVTo7aGXyZ2HnPsc/x41eJz9dL4q2AC8xo4kfBie8BTVmG6V3iT24vm13/vN+IF2iFnqa19LwginwvJUiIxC9HgxkgKoIf11efQH8P3O83vJjNFpDKZ/OUxCT4gsT8GhXlHC9eMZx5S5BzliV+oeT2rRcLyXUW/QfGf4kCpRCHuzf7o4tpZ/99HJZir1BVAvgVondGUaBWmqniHKgcIAl3jG9q8m1baWMxBsEUT2GE5HzE2QpnkBlD5IgIsAqSP2Q3wFcEZBnEKB4u0qWwEkcLtB7D/dCc9Ac9OpBr2TxpRm97UXTW7UTt3tuWVSi+t1XmKuhFhOk0anV0oG4INEQzTHC+sazNiHGJiKOqYDF43liO4nC4f7H6GRYFQZtgIQrbrUIc6WHg+vi7W0i5gluugUT0nv2jTxUh4X9mPdnhwlHGJY0GTFFZQ43Lse1GDBiVsK6vqB3o5HrXixjE8WR/M2qG/EjNCE5tkaaho0DIyXhYT7RjwuAjEjDh7mjwHdOMPYjjU2a/qo6yL7agNIoWPIumrV73LDo9tT5EP3UL1dwwF4qzAkLNHywOwcqQ5uxQoOiuNEs99uTR2nHrc1iKCNQ4naYlW3QfPhozZ53u7hRVA0bRzxe3tu3xTQHf3GwfjdI4S/4W1g68Lmium/GlxKtjmxTT9slpt9fuvEHL4v2jhU4s7XIl6sQtK25mzFzKQrwLwzkSTYH0XgY5r+f/uXHZx1i6hu1TJd2ZeSeXf2WGKtA6Sn1W3aCvL6HtgX3JGhxqd3ff72y1MYbkCg6oQ8V2ZwQeXhwf6k9e11nao2docRdm60uRxIy68ktqZlQ87BrRdaWXXMPha57jmh8rtX0Zh9VPnX4jDssfOv3GH9+4/Po=
9RrcFT0ApvD85eMD
